Plain-English translation of NCT06355609 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II clinical trial testing whether two medications—sunvozertinib and anlotinib—work well together to treat advanced lung cancer in people whose tumors have specific genetic mutations (EGFR mutations plus additional genetic changes). About 52 patients will take both medications daily to see if the treatment slows cancer growth and is safe to use.
Many people with advanced lung cancer have tumors with EGFR mutations, but some of these tumors also have additional genetic changes that may make them harder to treat. This trial is testing whether combining two medications that target different pathways in cancer cells can work better than using one medication alone.
You likely qualify if…
You likely don't qualify if…
You would take sunvozertinib (one tablet) and anlotinib (one tablet) by mouth once daily. Anlotinib is taken for 2 weeks, then you have a 1-week break before starting the cycle again. You would continue treatment until your cancer stops responding, side effects become too difficult to manage, or your doctor decides to stop. The study will track how well the treatment works, any side effects you experience, and how long you survive.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Hunan Province Tumor Hospital
Enrollment target
~100 participants
Started
July 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yongchang Zhang
Hunan Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.